On November 6, 2020, Zimmer Biomet, a leading medical device manufacturer, announced in its earnings report that it has acquired Relign Corp., a privately held start-up in the growing $1.6 billion arthroscopy market and overall $5 billion sports medicine market. Relign’s offerings include the consolidation of three differentiated arthroscopy tower components into a single system, a first in the industry, and address a key portfolio gap for Zimmer Biomet in the sports medicine and broader ambulatory surgery center markets.
Wilson Sonsini Goodrich & Rosati represented Relign in the transaction. The team that advised Relign includes:
M&A
Rob Ishii
Rich Mullen
Erin Malone-Shkurkin
Elia Perez Villamarin
Corporate
Elton Satusky
IP and Technology Transactions
Alex Key
Miruna Predescu
Kexi Wang
Patent
Jim Heslin
Regulatory & Compliance
David Hoffmeister
Eva Yin
Employee Benefits and Compensation
Michael Klippert
Data and Privacy
Matt Staples
Daniel Chen
Employment
Aren Balabanian
JeAnne Reyes
Real Estate
Jim McCann
For more information, please see Zimmer Biomet’s press release.